FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914232289> ?p ?o ?g. }

• W2914232289 abstract "Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment for depression, which may further impact clinical antidepressant treatment recommendations. This study evaluated PK and PD genetic variation and the clinical use of such testing in treatment seeking patients with bipolar disorder (BP) and major depressive disorder (MDD) and history of multiple drug failures/treatment resistance. Methods: Consecutive depressed patients evaluated at the Mayo Clinic Depression Center over a 10-year study time frame (2003-2013) were included in this retrospective analysis. Diagnoses of BP or MDD were confirmed using a semi-structured diagnostic interview. Clinical rating scales included the Hamilton Rating Scale for Depression (HRSD24), Generalized Anxiety Disorder 7-item scale (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Adverse Childhood Experiences (ACE) Questionnaire. Clinically selected patients underwent genotyping of cytochrome P450 CYP2D6/CYP2C19 and the serotonin transporter SLC6A4. PK and PD differences and whether clinicians incorporated test results in providing recommendations were compared between the two patient groups. Results: Of the 1795 patients, 167/523 (31.9%) with BP and 446/1272 (35.1%) with MDD were genotyped. Genotyped patients had significantly higher self-report measures of depression and anxiety compared to non-genotyped patients. There were significantly more CYP2C19 poor metabolizer (PM) phenotypes in BP (9.3%) vs. MDD patients (1.7%, p = 0.003); among participants with an S-allele, the rate of CYP2C19 PM phenotype was even higher in the BP (9.8%) vs. MDD (0.6%, p = 0.003). There was a significant difference in the distribution of SLC6A4 genotypes between BP (l/l = 28.1%, s/l = 59.3%, s/s = 12.6%) and MDD (l/l = 31.4%, s/l = 46.1%, s/s = 22.7%) patients (p < 0.01). Conclusion: There may be underlying pharmacogenomic differences in treatment seeking depressed patients that potentially have impact on serum levels of CYP2C19 metabolized antidepressants (i.e., citalopram / escitalopram) contributing to rates of efficacy vs. side effect burden with additional potential risk of antidepressant response vs. induced mania. The evidence for utilizing pharmacogenomics-guided therapy in MDD and BP is still developing with a much needed focus on drug safety, side effect burden, and treatment adherence." @default.
• W2914232289 created "2019-02-21" @default.
• W2914232289 creator A5015727111 @default.
• W2914232289 creator A5028939830 @default.
• W2914232289 creator A5029433360 @default.
• W2914232289 creator A5032284161 @default.
• W2914232289 creator A5038312444 @default.
• W2914232289 creator A5039884481 @default.
• W2914232289 creator A5046136151 @default.
• W2914232289 creator A5050515785 @default.
• W2914232289 creator A5051013000 @default.
• W2914232289 creator A5051342376 @default.
• W2914232289 creator A5053436606 @default.
• W2914232289 creator A5053799877 @default.
• W2914232289 creator A5058499524 @default.
• W2914232289 creator A5062505199 @default.
• W2914232289 creator A5067652247 @default.
• W2914232289 creator A5090955632 @default.
• W2914232289 creator A5091593979 @default.
• W2914232289 date "2019-02-19" @default.
• W2914232289 modified "2023-10-16" @default.
• W2914232289 title "Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications" @default.
• W2914232289 cites W1967503052 @default.
• W2914232289 cites W1981459575 @default.
• W2914232289 cites W1984455353 @default.
• W2914232289 cites W1984615306 @default.
• W2914232289 cites W2003385727 @default.
• W2914232289 cites W2019465651 @default.
• W2914232289 cites W2021977055 @default.
• W2914232289 cites W2022031948 @default.
• W2914232289 cites W2025779989 @default.
• W2914232289 cites W2035090322 @default.
• W2914232289 cites W2043705607 @default.
• W2914232289 cites W2045227722 @default.
• W2914232289 cites W2050603486 @default.
• W2914232289 cites W2059997499 @default.
• W2914232289 cites W2064554173 @default.
• W2914232289 cites W2066671649 @default.
• W2914232289 cites W2069365138 @default.
• W2914232289 cites W2071493584 @default.
• W2914232289 cites W2087527374 @default.
• W2914232289 cites W2094119604 @default.
• W2914232289 cites W2096991502 @default.
• W2914232289 cites W2098082628 @default.
• W2914232289 cites W2107807525 @default.
• W2914232289 cites W2114613490 @default.
• W2914232289 cites W2116839388 @default.
• W2914232289 cites W2132324173 @default.
• W2914232289 cites W2140660757 @default.
• W2914232289 cites W2146103479 @default.
• W2914232289 cites W2151135161 @default.
• W2914232289 cites W2156104108 @default.
• W2914232289 cites W2161620765 @default.
• W2914232289 cites W2162196924 @default.
• W2914232289 cites W2411285768 @default.
• W2914232289 cites W2510734833 @default.
• W2914232289 cites W2562914031 @default.
• W2914232289 cites W2801125956 @default.
• W2914232289 cites W2803666843 @default.
• W2914232289 cites W2886309064 @default.
• W2914232289 cites W2904329429 @default.
• W2914232289 cites W2917243324 @default.
• W2914232289 cites W4299913321 @default.
• W2914232289 cites W4376044127 @default.
• W2914232289 cites W45763398 @default.
• W2914232289 doi "https://doi.org/10.3389/fphar.2019.00083" @default.
• W2914232289 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6389687" @default.
• W2914232289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30837869" @default.
• W2914232289 hasPublicationYear "2019" @default.
• W2914232289 type Work @default.
• W2914232289 sameAs 2914232289 @default.
• W2914232289 citedByCount "11" @default.
• W2914232289 countsByYear W29142322892020 @default.
• W2914232289 countsByYear W29142322892022 @default.
• W2914232289 countsByYear W29142322892023 @default.
• W2914232289 crossrefType "journal-article" @default.
• W2914232289 hasAuthorship W2914232289A5015727111 @default.
• W2914232289 hasAuthorship W2914232289A5028939830 @default.
• W2914232289 hasAuthorship W2914232289A5029433360 @default.
• W2914232289 hasAuthorship W2914232289A5032284161 @default.
• W2914232289 hasAuthorship W2914232289A5038312444 @default.
• W2914232289 hasAuthorship W2914232289A5039884481 @default.
• W2914232289 hasAuthorship W2914232289A5046136151 @default.
• W2914232289 hasAuthorship W2914232289A5050515785 @default.
• W2914232289 hasAuthorship W2914232289A5051013000 @default.
• W2914232289 hasAuthorship W2914232289A5051342376 @default.
• W2914232289 hasAuthorship W2914232289A5053436606 @default.
• W2914232289 hasAuthorship W2914232289A5053799877 @default.
• W2914232289 hasAuthorship W2914232289A5058499524 @default.
• W2914232289 hasAuthorship W2914232289A5062505199 @default.
• W2914232289 hasAuthorship W2914232289A5067652247 @default.
• W2914232289 hasAuthorship W2914232289A5090955632 @default.
• W2914232289 hasAuthorship W2914232289A5091593979 @default.
• W2914232289 hasBestOaLocation W29142322891 @default.
• W2914232289 hasConcept C118552586 @default.
• W2914232289 hasConcept C126322002 @default.
• W2914232289 hasConcept C139719470 @default.
• W2914232289 hasConcept C140840227 @default.
• W2914232289 hasConcept C162324750 @default.
• W2914232289 hasConcept C170734499 @default.

• next